Similar companies
Income Statement (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Revenue | 41M | 47.8% |
| Gross Profit | -18M | 24.9% |
| Cost of Revenue | 59M | 14% |
| Operating expense | 71M | 11.7% |
| Net Income | -33M | 6.8% |
| EBITDA | -33M | 11.7% |
Balance Sheet (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Total Assets | 377M | 7.9% |
| Total Liabilities | 125M | 68.2% |
| Total Equity | 252M | 8.3% |
| Shares Outstanding | 38M | 0.7% |
Cash Flow (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Cash from operations | -14M | 61.9% |
| Cash from investing | -41M | 60.4% |
| Cash from financing | 42M | 61.1% |
EPS
Financial Highlights for Tarsus Pharmaceuticals in Q2 '24
Tarsus Pharmaceuticals reported a revenue of 41M, which is a 47.8% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at -18M, marking a 24.9% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 59M, a 14% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 71M, showing a 11.7% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -33M, showing a 6.8% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -33M, showing a 11.7% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Tarsus Pharmaceuticals with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
